. 2021 Aug 19;36(2):482–491. doi: 10.1038/s41375-021-01387-y

Table 2.

Multi-variable analyses.

Variable	CCyR		MMR		MR⁴		MR^4.5		FFS		PFS		Survival		CML-related survival
Variable	HR (95%CI)	p value	HR (95%CI)	p value	HR (95%CI)	p value	HR (95%CI)	p value	HR (95%CI)	p value	HR (95%CI)	p value	HR (95%CI)	p value	HR (95%CI)	p value
All subjects
Sokal risk		<0.001		0.003						<0.001		0.008		0.063
Low (ref.)
Intermediate	0.8 (0.7, 0.9)	0.004	0.8 (0.7, 0.9)	0.002					1.7 (1.2, 2.3)	0.001	2.2 (1.3, 3.8)	0.002	2.3 (1.1, 4.6)	0.026
High	0.7 (0.6, 0.8)	<0.001	0.8 (0.7, 0.9)	0.012					2.0 (1.4, 2.8)	<0.001	1.6 (0.9, 2.9)	0.091	1.8 (0.8, 3.9)	0.143
ELTS risk		0.001		<0.001		0.010		0.022		<0.001		<0.001		<0.001		<0.001
Low (ref.)
Intermediate	0.9 (0.7, 1.0)	0.080	0.8 (0.6, 0.9)	0.003	0.8 (0.6, 1.0)	0.028	0.8 (0.6, 1.0)	0.041	1.5 (1.1, 2.0)	0.004	1.7 (1.0, 2.7)	0.035	1.8 (1.0, 3.2)	0.063	1.4 (0.8, 2.7)	0.227
High	0.6 (0.5, 0.8)	<0.001	0.6 (0.4, 0.8)	<0.001	0.6 (0.4, 0.9)	0.013	0.6 (0.4, 0.9)	0.030	2.5 (1.8, 3.5)	<0.001	4.0 (2.3, 7.0)	<0.001	5.0 (2.7, 9.1)	<0.001	4.3 (2.3, 8.1)	<0.001
Female (ref. male)			1.4 (1.2, 1.6)	<0.001	1.2 (1.0, 1.4)	0.028	1.5 (1.2, 1.8)	<0.001
WBC, ×10E + 9/L (Continuous)	0.9 (0.9, 1.0)	0.069	0.9 (0.8, 0.9)	<0.001	0.8 (0.7, 0.9)	<0.001	0.7 (0.6, 0.8)	<0.001			0.9 (0.7, 1.0)	0.053
Haemoglobin, g/L (Continuous)	1.1 (1.0, 1.1)	<0.001	1.1 (1.1, 1.1)	<0.001	1.0 (1.0, 1.0)	<0.001	1.1 (1.0, 1.1)	0.003	0.9 (0.8, 0.9)	<0.001	0.8 (0.7, 0.9)	<0.001	0.9 (0.8, 1.0)	0.009	0.8 (0.8, 0.9)	0.004
2G-TKI (ref. Imatinib)	1.6 (1.4, 1.9)	<0.001	1.4 (1.2, 1.7)	<0.001	1.4 (1.1, 1.7)	0.002	1.5 (1.2, 1.9)	0.002
Imatinib cohort
Sokal risk		<0.001		0.073						<0.001		0.004		0.058
Low (ref.)
Intermediate	0.8 (0.7, 0.9)	0.007	0.9 (0.8, 1.0)	0.125					2.2 (1.6, 3.1)	<0.001	2.3 (1.4, 3.8)	0.001	2.8 (1.2, 6.4)	0.014
High	0.7 (0.6, 0.8)	<0.001	0.8 (0.7, 1.0)	0.030					2.6 (1.8, 3.7)	<0.001	1.5 (0.9, 2.7)	0.156	2.5 (1.0, 6.0)	0.069
ELTS risk		0.001		<0.001		0.001		0.017		<0.001		<0.001		<0.001		<0.001
Low (ref.)
Intermediate	0.9 (0.7, 1.0)	0.071	0.7 (0.6, 0.9)	<0.001	0.7 (0.5, 0.9)	0.001	0.7 (0.5, 1.0)	0.032	1.3 (1.0, 1.8)	0.003	1.7 (1.0, 2.7)	0.035	1.8 (1.0, 3.2)	0.063	1.7 (0.8, 3.4)	0.137
High	0.6 (0.5, 0.8)	<0.001	0.8 (0.5, 0.9)	0.011	0.6 (0.4, 0.9)	0.027	0.5 (0.3, 0.9)	0.029	2.2 (1.5, 3.2)	<0.001	3.9 (2.2, 6.7)	<0.001	5.0 (2.7, 9.1)	<0.001	5.1 (2.5, 10.5)	<0.001
Female (ref. male)			1.3 (1.1, 1.5)	<0.001	1.2 (1.1, 1.4)	0.023	1.4 (1.2, 1.8)	<0.001	0.8 (0.6, 0.9)	0.032
WBC, ×10E + 9/L (Continuous)	0.9 (0.9, 1.0)	0.002	0.9 (0.8, 0.9)	<0.001	0.8 (0.7, 0.9)	<0.001	0.6 (0.5, 0.7)	<0.001
Haemoglobin, g/L (Continuous)	1.1 (1.0, 1.2)	<0.001	1.1 (1.1, 1.2)	<0.001	1.1 (1.0, 1.2)	0.001	1.1 (1.0, 1.1)	0.003	0.8 (0.8, 0.9)	<0.001	0.8 (0.7, 0.9)	<0.001	0.8 (0.7, 0.9)	<0.001	0.8 (0.7, 0.9)	0.003
2G-TKI cohort
ELTS risk		<0.001		0.007		0.039				<0.001		0.003
Low (ref.)
Intermediate	0.7 (0.5, 1.0)	0.033	1.0 (0.7, 1.3)	0.623	0.9 (0.6, 1.4)	0.668			1.1 (0.6, 2.0)	0.799	1.2 (0.5, 3.2)	0.703
High	0.4 (0.2, 0.6)	<0.001	0.4 (0.3, 0.7)	0.002	0.4 (0.2, 0.9)	0.024			3.5 (1.9, 6.2)	<0.001	4.1 (1.7, 9.9)	0.002
Female (ref. male)			1.5 (1.1, 2.0)	0.008	1.5 (1.1, 1.9)	0.009	1.6 (1.1, 2.3)	0.020
WBC, ×10E + 9/L (Continuous)					0.9 (0.9, 1.0)	<0.001	0.7 (0.6, 0.8)	<0.001
Haemoglobin, g/L (Continuous)	1.1 (1.0, 1.2)	0.055	1.1 (1.0, 1.2)	0.005

CCyR complete cytogenetic response, CI confidence interval, FFS failure-free survival, HR hazard ratio, MMR major molecular response, MR^4.5 molecular response 4.5, PFS progression-free survival.